Hi Kogarah Boy,
I have not paid too much attention to Immunotherapies apart from getting an understanding about the funding. I wouldn’t hold too much hope for a phase 2b HSV2 trial as it is a super long shot. However, as it is around the time they would like to consider an IPO then it may add to the buzz and potential at the time.
I think the HPV studies is where it is at. The combination with Astra Zeneca’s checkpoint inhibitor ant-PD-L1 could be very interesting next year. If it shows promise it could lead to a partnership of some kind. Astra Zeneca is a $68 billion dollar giant.
Our first patient for Head and Neck has already been dowsed and the phase 1A safety study should be completed by years end. So we have news flow to come.
As far as your questions relating to HSV2 and China I am not sure but others seem to know a bit about it.
What does this mean, page-23
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.20 |
Change
-0.550(5.12%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $10.73 | $10.73 | $10.15 | $109.7K | 10.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 490 | $10.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.20 | 911 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |